October 30, 2024
Xilio Therapeutics to Present Initial Phase 1C Dose Escalation Data for XTX101 (Vilastobart) in Combination with Atezolizumab in a Late-Breaker Poster at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting
October 4, 2024
Xilio Therapeutics Announces Upcoming Poster Presentation at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting
October 2, 2024
Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
August 28, 2024
Xilio Therapeutics to Present at Morgan Stanley 22nd Annual Global Healthcare Conference
August 8, 2024
Xilio Therapeutics Announces Pipeline and Business Updates and Second Quarter 2024 Financial Results
June 13, 2024
Xilio Therapeutics Appoints Aoife Brennan, M.D., and James Shannon, M.D., to its Board of Directors
May 14, 2024
Xilio Therapeutics Announces Pipeline and Business Updates and First Quarter 2024 Financial Results
April 1, 2024
Xilio Therapeutics Announces Pipeline and Business Updates and Fourth Quarter and Full Year 2023 Financial Results
March 28, 2024
Xilio Therapeutics Announces $11.3 Million Private Placement Equity Financing
March 28, 2024
Gilead and Xilio Announce Exclusive License Agreement for Tumor-Activated IL-12 Program
Displaying 1 - 10 of 13